ClinicalTrials.gg
RecruitingNCT05649488Updated Apr 13, 2023

Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

An interventional study of Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus and Dragonfly Opstar Imaging Catheter in Coronary Artery Disease and Intravascular Lithotripsy, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..

Planned enrollment
10th of 16
184 · median 200
Started
2023
the only one that year
No phase
16 of 23
7 open now
Primary completion
2024-12
later than 2 of 10 live
Registered
16th of 23
by date

Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is one of 16 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., or all of them as a file.
02

Study summary

This is a prospective, multi-center, single-group target value clinical trial, which will be carried out in many clinical trial institutions in China. A total of 184 subjects (70 of them are OCT subgroups) are planned to be enrolled, all subjects were treated surgically with intracoronary lithotripsy using a balloon dilatation catheter and intracoronary lithotripsy apparatus after a single-group registration, clinical follow-up was carried out within 7 days after operation or before discharge, 1 month and 6 months after operation. The success rate of operation was taken as the main end point to verify the effectiveness of balloon dilatation catheter and intracoronary lithotripsy apparatus.

Read the detailed description

This is a prospective, multi-center, single-group target value clinical trial to recruit patients with coronary artery calcification, coronary artery calcification was pretreated with balloon dilatation catheter and intracoronary lithotripsy apparatus made by Shanghai Blusail Boyuan Medical Technology Co. , Ltd. , to verify the safety and efficacy of balloon dilatation catheter and intracoronary lithotripsy instrument for intravascular preconditioning of coronary artery calcification lesions. This trial will be carried out in many clinical trial institutions in China, and a total of 184 subjects (70 of them are OCT subgroups) are planned to be enrolled, all subjects were treated surgically with intracoronary lithotripsy using a balloon dilatation catheter and intracoronary lithotripsy apparatus after a single-group registration, clinical follow-up was carried out within 7 days after operation or before discharge, 1 month and 6 months after operation. In this study, the success rate of operation was taken as the main end point to verify the effectiveness of balloon dilatation catheter and intracoronary lithotripsy apparatus. A clinical summary report was issued for registration of the product 1 month after completion of postoperative follow-up, based on which a 6-month postoperative follow-up was performed to assess its safety. The secondary end points were angiographic success, device success, target lesion failure at 1 and 6 months, severe angiographic complications, MACE events at 1 and 6 months, serious adverse events and adverse events, and device defects. In the OCT Subgroup, the secondary end points were the minimum stent area (MSA), the minimum stent lumen diameter (MLD), the lumen acquired diameter, the lumen acquired area, and the lumen acquired rate of the immediate postoperative, the expansion rate of the stent, and the incomplete adherence rate of the stent beam.

03

Conditions studied

  • Coronary Artery Disease
  • Intravascular Lithotripsy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years, male or non-pregnant female.
  2. Evidence of symptomatic ischemia, stable or unstable angina, or MI for more than 7 days.
  3. Patients who can understand the purpose of the trial, voluntarily participate and sign the form, and are willing to undergo angiography, OCT and clinical follow-up.

Angiogram inclusion criteria

  1. The target lesion was primary and in situ coronary artery disease.
  2. Target lesion length ≤40 mm, target lesion reference vessel diameter 2.25-4.0 mm (visual inspection).
  3. The target lesion diameter stenosis ≥70% or ≥50% (visual inspection) with evidence of ischemia.
  4. Clear, high-density shadows can be seen both when the heart is beating and when it is not.
  5. TIMI flow grade 3(allowing predilation) in the target vessel before use of the test equipment.
  6. The target lesion was the only calcified lesion to be treated with the shock wave, and the non-target lesion needed to be treated successfully before the target lesion.
  7. Suitable for patients undergoing metallic stent implantation

Exclusion criteria

Exclusion Criteria:

  1. Severe myocardial infarction occurred within 7 days before operation.
  2. At the same time, the lesions were treated with rotational grinding or special balloon (chocolate balloon, nicked balloon, cutting balloon, double guide wire balloon, spinous process balloon, etc.).
  3. Class III or IV.
  4. \<35% .
  5. The target lesion was expected to be treated by fully biodegradable stent implantation, drug balloon dilatation and PTCA.
  6. Uncontrollable severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg).
  7. Severe hepatic and renal impairment, transaminase more than 3 times the , serum creatinine > 2.5 mg/dL (221 μmol/L), or chronic kidney failure requiring long-term dialysis.
  8. Preoperative \<100 g/l.
  9. count \<60×109/L.
  10. Cerebral Stroke occurred within 6 months of enrollment, excluding (TIA) and lacunar infarction.
  11. A history of active peptic ulcer or upper gastrointestinal bleeding within 6 months before enrollment.
  12. Patients known to be allergic to heparin, contrast media, aspirin, clopidogrel and anesthetics.
  13. Definite diagnosis of or would be less than 12 months.
  14. Participation in clinical trials of other drugs or medical devices that did not reach the primary end point.
  15. The researchers judged that the patients had poor compliance and could not complete the study according to the protocol.

Angiographic exclusion criteria:

  1. The target lesion was in the opening position (LAD, LCX or RCA, within 5 mm of the opening) or unprotected left main coronary artery.
  2. Stents were implanted 10mm proximal or distal to the target lesion.
  3. The target lesion had unprotected branch vessels more than 2.5mm in diameter.
  4. The target lesion was distal to the saphenous vein or LIMA (Left internal mammary artery) /RIMA (Right internal mammary artery) bypass graft.
  5. Existed an aneurysm within 10mm of the target lesion.
  6. Angiography confirmed the presence of severe target lesion dissection (type D-F dissection (NHLBI classification) before the treatment of the Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus
  7. The target lesion had definite thrombosis.
  8. The researchers determined that the target lesion was unsuitable for vasodilation in patients.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Experimental group

    184 patients were enrolled in the experimental group

    Device: Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus

  • Other
    Optical Coherence Tomography Subgroup

    70 patients in the test group were enrolled in the OCT subgroup.

    Device: Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus · Device: Dragonfly Opstar Imaging Catheter

Interventions

  • DeviceIntracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus

    Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle. Therapeutic apparatus specification: IVL-HVG-C01; Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015

  • DeviceDragonfly Opstar Imaging Catheter

    OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.

06

What researchers measure

Primary outcomes

  1. Operation success rate

    After successful stent placement, the residual stenosis in the stent is ≤ 30%, and there is no residual stenosis during hospitalization (up to 7 days after surgery at most) MACE event occurs

    Time frame: During hospitalization (up to 7 days after operation)

Secondary outcomes

  1. Angiographic success rate (residual stenosis ≤ 30%)

    Efficacy endpoint

    Time frame: Immediately after operation

  2. Incidence rate of MACE events 1 month and 6 months after operation

    Security endpoint

    Time frame: 6 months after operation

  3. Target lesion failure (TLF) rate 1 month and 6 months after operation

    Security endpoint

    Time frame: 6 months after operation

  4. Device success rate

    Security endpoint

    Time frame: 6 months after operation

  5. Incidence of serious angiographic complications

    Security endpoint

    Time frame: 6 months after operation

  6. Incidence rate of serious adverse events and adverse events

    Security endpoint

    Time frame: 6 months after operation

  7. Incidence rate of device defects

    Security endpoint

    Time frame: 6 months after operation

Other outcomes

  1. Minimum stent area (MSA) immediately after operation

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  2. Minimum stent lumen diameter (MLD) immediately after operation

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  3. Diameter of lumen obtained immediately after operation

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  4. Area of lumen obtained immediately after operation

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  5. Acquisition rate of lumen immediately after operation

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  6. Support expansion rate

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

  7. Incomplete adherence rate of support beam

    Secondary destination of OCT subgroup

    Time frame: Immediately after operation

07

Study locations

11 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2024, 21 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 21 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 14, 2022
StartActual
Feb 9, 2023
Primary completionEst.
Dec 1, 2024
CompletionEst.
Sep 22, 2025
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05649488
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Feb 9, 2023
Primary completion
Dec 1, 2024 (estimated)
Completion
Sep 22, 2025 (estimated)
Last update
Apr 13, 2023

Study contacts

Yanjiao Zhang, PM
Contact
yanjiao.zhang@jwmsgrp.com
+8613889120902
Ying Chang, Master
Contact
c.chang@jwmsgrp.com
+8613701259639
Yaling Han, Ph.D
principal investigator · The General Hospital of Northern Theater Command

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion